ETCTN Trials by Disease/Treatment Area: Gastrointestinal Cancer

### Colorectal cancer
- Adenocarcinoma of the rectum
- MET amplified adenocarcinoma of the colon/rectum
- Metastatic colorectal cancer, not otherwise stated

### Gastroesophageal cancer
- Gastric and gastroesophageal junction adenocarcinoma

### Liver and hepatobiliary cancer
- Cholangiocarcinoma
- Cholangiocarcinoma/gallbladder carcinoma
- Mesothelin-positive advanced pancreatic adenocarcinoma

### Pancreatic cancer
- Pancreatic ductal adenocarcinoma
- Locally advanced, pancreatic adenocarcinoma

### Anal cancer
- Squamous cell carcinoma of the anus

### Peritoneal mesothelioma
- Peritoneal mesothelioma

### Liver and hepatobiliary cancer

- **10058**: A Phase I Study of Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum

- **10181**: A Phase II Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer

- **9676**: A Phase I Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Cancers (Expansion phase, pt.1 includes melanoma, renal cell, ovarian, and colorectal cancer)

- **10066**: A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)

- **10211**: A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer

- **10222**: Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH)-Mutant Solid Tumors (2 cohorts: cholangiocarcinoma and other solid tumors)

- **10129**: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors (3 cohorts: glioma, cholangiocarcinoma, and other solid tumors)

- **10276**: A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (Phase 1: advanced/metastatic solid tumors; Phase 2: advanced/metastatic hepatobiliary tumors)

- **10208**: A Phase III study of Axitinib and Axitinib in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (Phase 1: advanced/metastatic solid tumors; Phase 2: advanced/metastatic hepatobiliary tumors)

### Pancreatic cancer

- **9831**: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (4 cohorts: NSCLC, TNBC, PDAC, and SCLC)

- **10366**: A Phase 1/2 Study of M3814 in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

### Anal cancer

- **9673**: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anus

- **9837**: Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin (Arm A: advanced solid tumors; Arm B: malignant pleural or peritoneal mesothelioma)

**Note**: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: September 17, 2019